A meta-analysis of liquid biopsy versus tumor histology for detecting EGFR mutations in non-small cell lung cancer
Translational Oncology · 2024-09 · 47 · 102022
DOI: 10.1016/j.tranon.2024.102022 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Translational Oncology, 2024-09. Verfasst von Jing Cai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, China-Japan Union Hospital of Jilin University, Changchun 130033, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jilin Provincial Natural Science Foundation, National Natural Science Foundation of China, Jilin Provincial Science and Technology Department.
Abstract (Originalsprache)
OBJECTIVE: To assess the consistency of liquid biopsy and histologic analysis for detecting epidermal growth factor receptor (EGFR) gene mutations in patients with advanced non-small cell lung cancer (NSCLC). METHODS: The PubMed, Cochrane Library, and CNKI et al. databases were searched to collect studies comparing liquid biopsy and histopathologic specimens. The EGFR mutation status was extracted from the studies, and meta-analysis was carried out using Stata 12.0 software. RESULTS: We included 22 studies of 3359 NSCLC patients. In the meta-analysis, eight papers with a sample size of size 50 %, showing that literature that did not include the T790M mutation was more heterogeneous. The combined diagnostic effect size of 34 in the exon 19 group was smaller than that in the group with no exon 19, with an I2>50 %. There was substantial heterogeneity in both the exon 19 group and the non-exon 19 group. The group with the L858R mutation had a greater diagnostic effect size of 28, lower I2, and less heterogeneity than the group without the L858R mutation. The exon 21 group had a larger pooled diagnostic effect size of 66, a smaller I2, and less heterogeneity than the group without exon 21. CONCLUSION: Liquid biopsy and histologic analysis have high concordance for detecting EGFR mutations in NSCLC. Liquid biopsy can provide an alternative technology for individualized treatment and monitoring of minimal residual disease (MRD) in advanced NSCLC patients with EGFR tyrosine kinase inhibitor-sensitive and drug resistance (T790M) mutations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, China-Japan Union Hospital of Jilin University, Changchun 130033, China.
- Department of Nephrology, the First Hospital of Jilin University, Changchun 130021, China.
- Department of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun 130033, China. Electronic address: wenxu@jlu.edu.cn.
Förderung
- Jilin Provincial Natural Science Foundation
- National Natural Science Foundation of China
- Jilin Provincial Science and Technology Department
Zitieren
APA
Cai, J., Wang, W., & Zhang, W. (2024). A meta-analysis of liquid biopsy versus tumor histology for detecting EGFR mutations in non-small cell lung cancer. Translational Oncology, 47, 102022. https://doi.org/10.1016/j.tranon.2024.102022
Vancouver
Cai J, Wang W, Zhang W. A meta-analysis of liquid biopsy versus tumor histology for detecting EGFR mutations in non-small cell lung cancer. Translational Oncology. 2024;47:102022. doi:10.1016/j.tranon.2024.102022
BibTeX
@article{Cai2024,
author = {Cai, Jing and Wang, Wanning and Zhang, Wenlong},
title = {A meta-analysis of liquid biopsy versus tumor histology for detecting EGFR mutations in non-small cell lung cancer},
journal = {Translational Oncology},
year = {2024},
volume = {47},
pages = {102022},
doi = {10.1016/j.tranon.2024.102022}
}
EUVIMED